I happened to be reading a thread for IMUGENE (the cancer killing company). A poster today wondered why JP Morgan Australia seems to have disposed of their holdings in IMU. And I thought “maybe to buy EBR shares”. Well they have, haven’t they? We have a clear pipeline to commercialisation, and a relatively easy to understand product with no competition in their category. Whereas IMU are relying on big pharma to make an offer, we already know EBR will target 45 practices that participated in the trials, aiming for 6 sales each for $US 35000 in their first year after FDA Approval. We can assume 100% growth. I found a fun way to estimate a share’s intrinsic value see https://www.omnicalculator.com/finance/intrinsic-value
Assuming funds compete with a corporate bond rate of 4%, EBR’s shares will have an intrinsic value of $7.06 in their first year of trading. Ok so I didn’t allow for costs in the earnings per share field, but still I used US dollars so that should compensate!
As they say in the classics, do your own research.
- Forums
- ASX - By Stock
- EBR
- General Investor Information EBR Systems
General Investor Information EBR Systems, page-215
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EBR (ASX) to my watchlist
(20min delay)
|
|||||
Last
88.0¢ |
Change
0.055(6.67%) |
Mkt cap ! $320.3M |
Open | High | Low | Value | Volume |
82.0¢ | 88.0¢ | 82.0¢ | $1.733M | 2.081M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9824 | 86.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
88.0¢ | 32650 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9824 | 0.865 |
2 | 16627 | 0.860 |
1 | 20000 | 0.850 |
1 | 30000 | 0.845 |
1 | 272 | 0.835 |
Price($) | Vol. | No. |
---|---|---|
0.880 | 4999 | 1 |
0.895 | 16660 | 2 |
0.900 | 55481 | 3 |
0.940 | 21276 | 1 |
0.950 | 10000 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
EBR (ASX) Chart |